Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Prednisone

FDA-approved product (tablet, oral), marketed as Cortan, Delta-Dome, Deltasone and 10 more.

Registered studies
50+
Lab records
0
Pathogens at ≥40%
1 of 4

Chemical structure

Chemical structure of Prednisone
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Adrenal gland disease
  • Allergic conjunctivitis
  • Allergic rhinitis
  • Anemia
  • Ankylosing spondylitis
  • Aplastic anemia
  • Arthritis
  • Asthma
  • Atopic eczema
  • Autoimmune thrombocytopenic purpura
  • Berylliosis
  • Brain neoplasm
  • Bursitis
  • Cancer
  • Chorioretinitis
  • Choroiditis
  • and 60 more

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Corticosteroids for local oral treatment; Corticosteroids acting locally; Corticosteroids; Corticosteroids, weak (group i); Corticosteroids, weak, other combinations
FDA pharmacologic class
Corticosteroid FDA label ↗
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against MRSA. It was surfaced computationally for further investigation; it is not an established treatment for this infection.

AI-predicted activity

AI prediction · nothing measured
  • MRSA46.4% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli30.6% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae17.7% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis35.2% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Prednisone in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

Not yet docked: queued in the docking rundetails

KPC-2 carbapenemase ↗ (K. pneumoniae)

Not yet docked: queued in the docking rundetails

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

Not yet docked: queued in the docking rundetails

Dihydrofolate reductase ↗ (MRSA)

Not yet docked: queued in the docking rundetails

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Prednisone with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Tacrolimus Versus Cyclophosphamide as Treatment for Lupus Nephritis

    NCT01207297 · start 2003-03

    Registered record
    Registry ID
    NCT01207297
    Conditions
    SLE; Lupus Nephritis; Renal Insufficiency; End-stage Renal Disease
    Interventions
    Tacrolimus; cyclophosphamide
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2003-03
    Completion
    2010-06
    Enrolment
    40

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSLE; Lupus Nephritis; Renal Insufficiency; End-stage Renal Disease
    InterventionTacrolimus; cyclophosphamide
    PhasePhase 1
    Registry statusCompleted

  • Study Comparing the Safety and Efficacy of Belatacept With That of Cyclosporine in Patients With a Transplanted Kidney

    NCT00035555 · start 2001-03

    Registered record
    Registry ID
    NCT00035555
    Conditions
    Graft Rejection; Kidney Transplantation; Renal Transplantation
    Interventions
    Belatacept; Cyclosporine; Mycophenolate mofetil (MMF); Corticosteroids
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2001-03
    Completion
    2012-07
    Enrolment
    230

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionGraft Rejection; Kidney Transplantation; Renal Transplantation
    InterventionBelatacept; Cyclosporine; Mycophenolate mofetil (MMF); Corticosteroids
    PhasePhase 2
    Registry statusCompleted

  • Mitoxantrone and Prednisone With or Without Leflunomide in Treating Patients With Stage IV Prostate Cancer

    NCT00004071 · start 1999-08

    Registered record
    Registry ID
    NCT00004071
    Conditions
    Prostate Cancer
    Interventions
    leflunomide; mitoxantrone hydrochloride; prednisone
    Study type
    INTERVENTIONAL
    Phase
    Phase 2 / Phase 3
    Registry status
    Completed
    Start
    1999-08
    Completion
    2007-09
    Enrolment
    Not recorded

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionProstate Cancer
    Interventionleflunomide; mitoxantrone hydrochloride; prednisone
    PhasePhase 2 / Phase 3
    Registry statusCompleted

  • Treatment of Patients With Idiopathic Membranous Nephropathy

    NCT00135954 · start 1997-07

    Registered record
    Registry ID
    NCT00135954
    Conditions
    Glomerulonephritis, Membranous
    Interventions
    Cyclophosphamide and steroids
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    1997-07
    Completion
    2008-07
    Enrolment
    29

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionGlomerulonephritis, Membranous
    InterventionCyclophosphamide and steroids
    PhasePhase 3
    Registry statusCompleted

  • Combination Chemotherapy in Treating Children With Lymphoma

    NCT00002590 · start 1994-07

    Registered record
    Registry ID
    NCT00002590
    Conditions
    Lymphoma
    Interventions
    filgrastim; cyclophosphamide; cytarabine; daunorubicin hydrochloride; doxorubicin hydrochloride; etoposide; leucovorin calcium; methotrexate; pegaspargase; prednisone; thioguanine; vincristine sulfate; radiation therapy
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    1994-07
    Completion
    2007-03
    Enrolment
    221

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionLymphoma
    Interventionfilgrastim; cyclophosphamide; cytarabine; daunorubicin hydrochloride +9 more
    PhasePhase 2
    Registry statusCompleted